- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Biogen: Anti-TNF Biosimilars Are Underutilized
Two Biogen officials make the case for getting anti–tumor necrosis factor (TNF) biosimilars into wider play.
Anti—tumor necrosis factor (TNF) biosimilars can provide a more cost-effective, targeted approach to treatment of immune-mediated inflammatory diseases, according to a review paper.
“Along the course of the last 2 decades, TNF inhibitors, particularly etanercept, infliximab and adalimumab, have revolutionized the management of chronic immune-mediated inflammatory diseases; however, their relatively high cost prevented healthcare systems from exploiting their full clinical benefit,” Mourad F. Rezk, MD, global head of Medical Affairs for Biogen's biosimilars portfolio, and Burkhard Pieper, director of Scientific Affairs for Biogen, wrote in Advances in Therapy.
The wealth of real-world evidence on these agents suggests that not only is use increasing but also these drugs are improving access and outcomes, they explained.
“This includes the opportunity to realize clinical goals such as early initiation of biological treatment, treating to target, continuing treatment to maintain remission or low disease activity and reducing disease burden,” they wrote.
However, optimizing these biosimilars requires that biosimilars be approved “expeditiously,” competition against originator drugs is “optimized,” and patients are switched to biosimilars. “All of these actions will result in maximum cost savings, which can then be reinvested into patient care,” they wrote.
Biogen turned in a good second-quarter 2020 financial performance, with modestly improved earnings; however, biosimilar revenues declined 7%.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.
